AI Article Synopsis

  • - The CAV-AEP has updated its annual vaccine guidelines for children, adolescents, and pregnant women in Spain, maintaining the 2+1 vaccination schedule for infants and emphasizing the need for a booster at age 6.
  • - Pregnant women are advised to receive a dose of dTap during each pregnancy, ideally between weeks 27 and 32, while infants should get vaccines for rotavirus, influenza, and MenACWY, among others.
  • - New recommendations include routine nirsevimab administration for infants to protect against RSV and HPV vaccination for all adolescents at age 12; updates for SARS-CoV-2 vaccines will be posted regularly on the CAV-AEP website.

Article Abstract

As it does every year, the CAV-AEP publishes the update of its recommendations for the use of vaccines in children, adolescents and pregnant women residing in Spain. The 2 + 1 schedule is maintained in infants (at 2, 4 and 11 months), including preterm infants, with the hexavalent vaccine (DTaP-IPV-Hib-HB) and the pneumococcal 13-valent conjugate vaccine. A booster dose with DTaP-IPV is needed at 6 years for those who received the 2 + 1 series with hexavalent vaccine as infants, in addition to 1 dose of dTap in adolescence. Routine vaccination of pregnant women with a dose of dTap is recommended in each pregnancy, preferably between weeks 27 and 32 of gestation, although can be given from 20 weeks if there is risk of preterm delivery. All infants should receive the rotavirus vaccine (2-3 doses) and the 4CMenB vaccine (2 + 1 series). All children aged 6-59 months should be vaccinated against influenza each year. The MenACWY vaccine should be given routinely at 12 months of age and in adolescence between ages 12 and 18 years. The recommendations for the MMR vaccine (12 months and 3-4 years) and varicella vaccine (15 months and 3-4 years) also remain unchanged, using the MMRV vaccine for the second dose. Recommendations for the use of SARS-CoV-2 vaccines in the paediatric age group will be updated periodically on the CAV-AEP website. The HPV vaccine is indicated in all adolescents, regardless of sex, at age 12 years. Novelties include the recommendation of routine administration of nirsevimab to neonates and infants aged less than 6 months for passive immunization against RSV, and the recommendations regarding the hexavalent vaccine are consolidated in a single section.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anpede.2022.11.002DOI Listing

Publication Analysis

Top Keywords

hexavalent vaccine
12
vaccine
11
pregnant women
8
2 + 1 series
8
dose dtap
8
vaccine months
8
months 3-4
8
3-4 years
8
months
6
recommendations
5

Similar Publications

Whole-Cell Vaccine Preparation Through Prussian Blue Nanoparticles-Elicited Immunogenic Cell Death and Loading in Gel Microneedles Patches.

Gels

December 2024

State Key Laboratory of Digital Medical Engineering, Basic Medicine Research and Innovation Center of Ministry of Education, Southeast University, Nanjing 211102, China.

Tumor whole-cell vaccines are designed to introduce a wide range of tumor-associated antigens into the body to counteract the immunosuppression caused by tumors. In cases of lymphoma of which the specific antigen is not yet determined, the tumor whole-cell vaccine offers distinct advantages. However, there is still a lack of research on an effective preparation method for the lymphoma whole-cell vaccine.

View Article and Find Full Text PDF

serovar Rissen ( Rissen) is an emerging causative agent of foodborne diseases. The current emergence of antibiotic resistance makes necessary alternative therapeutic strategies. In this study, we investigated the potential of a phage-resistant strain of Rissen (R) as a tool for developing an effective lipopolysaccharide (LPS)-based vaccine.

View Article and Find Full Text PDF

Despite the availability of a highly efficacious vaccine, a global resurgence of measles infections has occurred, largely due to decreased vaccination coverage and waning immunity following the two-dose vaccination schedule. This study aims to assess the cellular immune response in individuals who did not respond to the two-dose MMR vaccine and evaluate the efficacy and durability of immune responses after booster doses. An observational study was conducted involving 24 individuals who were seronegative for measles years after completing the two-dose MMR vaccine schedule.

View Article and Find Full Text PDF

Trichinellosis, a zoonotic disease transmitted through food and caused by , is a significant health concern worldwide. Therefore, developing a safe and effective vaccine to combat infection is essential. In this study, a nonantibiotic strain lacking the gene served as a live bacterial vector to deliver antigens to the host, creating a novel oral vaccine.

View Article and Find Full Text PDF

Background: Human papillomavirus (HPV) infection profoundly affects women living with HIV (WLWH). This infection leads to cervical cancer (CC) and increased mortality.

Methods: This study monitored HPV infection in WLWH in Rio de Janeiro, Brazil, before (T1) and after (T2) 4 years of vaccination.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!